ESMO20: can nivolumab–cabozantinib reduce risk of death in renal cell carcinoma?

Written by Ebony Torrington, Future Science Group

nivolumab plus cabozantinib

Results from the Phase III CheckMate -9ER trial presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 (19 – 21 September) have shown that the combination of Opdivo (nivolumab) and Cabometyx (cabozantinib) reduce the risk of death in people with previously untreated advanced renal cell carcinoma (RCC) by 40%, compared with Sutent (sunitinib) alone. “There is no doubt in my mind that this will be a major player as an initial treatment in this indication,” commented lead trial researcher Toni Choueiri (Dana Farber Cancer Institute, MA, USA). A total of 651 people with previously untreated advanced or...

To view this content, please register now for access

It's completely free